Tooth Replacement
Conditions
Keywords
Dental, Implant, UNC Dental School, Trabecular Metal, Titanium, Healthy Volunteers, Diabetic, Osteopenic, Bone Inductive Properties, Osseous Healing, GO Health, Offenbacher, Zimmer Dental, Inc.
Brief summary
The purpose of this research study is to compare the healing differences of two metals (trabecular vs. standard titanium) that are used for dental implants. In addition; investigators will be examine these differences in the gene expression profiles in subjects with three conditions associated with delayed healing: diabetes and osteoporosis. The study will last at least 11 weeks consisting of 6 appointments. All visits will be carried out at the GO Health Center within the UNC School of Dentistry. Visits will last between 30 minutes to 3 hours depending on the particular visit. The visits will consist of: Obtaining consent, doing a health history, measuring vital signs, doing dental exams of the teeth and gums, collecting samples of saliva dental radiographs (X-rays), a teeth cleaning, having 4 temporary mini test cylinders placed in areas of the lower jaw where teeth are missing and implant surgery to place up to four permanent implants.
Detailed description
The plan is to recruit subjects into 3 groups: 1) systemically healthy, 2) subjects with diabetes (ADA classification determined by glycosylated hemoglobin A1C levels), and 3) subjects with osteoporosis (limited to those on either no drugs or oral bisphosphonates only). All subjects recruited will have already been approved and treatment planned for implant placement by non-study personnel to avoid any potential conflict of interest. All subjects will have mandibular radiographs that show edentulous ridge areas that provide enough alveolar ridge space to place two test cylinders (each approximately 2.9-3 x 5mm) on each side of the mandible. One side will have two titanium test cylinders and the contralateral side will have two trabecular metal test cylinders. After placement of these 4 test cylinders, one will be removed contra laterally from each side at weeks 2 and 4 of healing. Thus, by 28 days all test cylinders will be removed. It has been our experience that each cylinder after removal will contain enough cells to provide approximately 10-20μg of total RNA. This quantity of total RNA is sufficient to run an Affymetrix chip and have enough mRNA for PCR confirmation. Sampling at 3 days after placement is too soon, as it does not provide adequate mRNA for the analysis, since the clot has not become remodeled or adequately organized to be cellular. Thus, by 1 week organization of the osseous healing will have begun and at week 2 it will be beginning to mature. The week 2 sampling time point) will provide us with early molecular kinetics of the healing response to compare the two metal surfaces and the differences in gene expression that may be associated with diabetes and osteoporosis. At weeks 2 and 4 the test cylinders will be removed using a 5.0 mm diameter tissue punch and a 5 mm trephine drill. Investigators will select 18 random patients (6 subjects per group) to provide (two test cylinders for each, 36 samples) for histology. Investigators will use the trephine drill to remove the 4 week test cylinders in all 3 groups of subjects. In all cases, a subject is eligible for this study by being pretreatment planned to receive a permanent implant bilaterally, which will be placed at donor sites. According to the participant's individual treatment plan, after test cylinders are removed, each site will receive an implant using either a standard 4.1 or 4.7 mm tapered screw vent design implant. The removed test cylinders will be briefly rinsed in saline and prepared chair side for either mRNA extraction or for histology.
Interventions
DEVICEZimmer Trabecular Metal Test Cylinder
For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
DEVICEZimmer Titanium Test Cylinder
For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
Sponsors
Zimmer Dental
University of North Carolina, Chapel Hill
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects must be adult males or females age 21 to 80 years (inclusive). * Subjects must be able and willing to follow study procedures and instructions in English. * Subjects must have read, understood and signed an informed consent form in English. * Subjects must have at least four mandibular implants as their future treatment needs. Subjects must meet one of the following categories to be considered for enrollment: * Group 1 (control): Subjects must be non-diabetic, no history of smoking within the last two years and no metabolic bone disease diagnosis. * Group 2 (diabetic): Subjects must have Type 2 diabetes mellitus as diagnosed by a physician or in medication history. The condition must be currently diagnosed and treated by medications and/or insulin. An HbA1C test performed either within past 3 months must be available or one will be done at the first visit by study personnel. Subjects must have no history of smoking within the last two years nor have any diagnosis of metabolic bone disease. * Group 3 (Osteoporosis or osteopenia): Subjects must be diagnosed with osteoporosis or osteopenia and must be currently under the care of a physician and treatment with oral bisphosphonates. Subjects must have never had intravenous (IV) bisphosphonates. Subjects in this group must be non-diabetic and no history of smoking within the last 2 years. Subjects undergoing test cylinder placement should be in adequate periodontal health prior to implant placement. This includes having probing depth ≤ 4 mm for all remaining teeth at the same quadrant of the proposed cylinder placement. Patients with periodontal probing sites with probing depths of up to 5 mm may also be included if bleeding on probing in these sites is absent. Each subject should be considered to be periodontally stable prior to receiving test cylinders.
Exclusion criteria
* Individuals who have a chronic disease with oral manifestations. * Individuals who exhibit gross oral pathology. * The use of either antibiotics or chronic use of NSAIDs within 1 month prior to screening examination. * Individuals that require antibiotic prophylaxis prior to dental treatment. * Chronic treatment (i.e. two weeks or more) with any medication known to affect periodontal status (e.g. phenytoin, calcium antagonists, cyclosporine, Coumadin) within 1 month prior to screening examination. * Systemic conditions, except diabetes, osteoporosis and osteopenia that are known to affect periodontal status. * Individual with uncontrolled parafunctional habits, such as clenching and bruxing on objects, that could adversely impact implant survival * Individuals with a history of intravenous bisphosphonates Individuals with active infectious diseases such as hepatitis, HIV or tuberculosis. * Individuals with a current tobacco use history. * Individuals who are known to be pregnant, breastfeeding or planning to become pregnant within 3 months. * Individuals with blood disorders and /or currently taking anticoagulants medications, unless he or she can provide a current International normalized ratio (INR) showing normal (0.8 - 2.0) values. * Individuals receiving any therapy known to affect healing, such as high dose corticosteroids, radiation therapy or chemotherapy. * Individuals allergic to topical or local anesthesia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | 2 weeks & 4 weeks post placement | Samples were analyzed comparing the osteogenic potential associated with titanium and porous tantalum dental implants (cylinders) at 2 and 4 weeks using transcriptome analyses. The primary outcome data are displayed showing the Average Delta ∆ (Ct) for osteogenic genes relative to the housekeeping markers. The numerical value of the CT is inversely related to the amount of amplicon in the reaction (i.e., the lower the CT, the greater the amount of amplicon). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | 4 weeks | Findings from expression arrays will be used to perform quantitative PCR analyses using SAB Superarrays (SuperArray GEArray), to enable a quantitativeassay of mRNA levels of specific inflammatory and growth factor molecules |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Healthy Volunteers Subjects who are non-diabetic, with no history of smoking within the past two years and no metabolic bone disease diagnosis.
Zimmer Trabecular Metal Test Cylinder: For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
Zimmer Titanium Test Cylinder: For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks. | 12 |
| Diabetic Subjects Subjects must have Type 2 diabetes mellitus as diagnosed by a physician or in medication history. The condition must be currently diagnosed and treated by medications and/or insulin.
Zimmer Trabecular Metal Test Cylinder: For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
Zimmer Titanium Test Cylinder: For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks. | 12 |
| Osteopenic Subjects Subjects must be diagnosed with osteoporosis or osteopenia and must be currently under the care of a physician and treatment with oral bisphosphonates
Zimmer Trabecular Metal Test Cylinder: For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
Zimmer Titanium Test Cylinder: For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks. | 8 |
| Total | 32 |
Baseline characteristics
| Characteristic | Diabetic Subjects | Osteopenic Subjects | Healthy Volunteers | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 7 Participants | 5 Participants | 4 Participants | 16 Participants |
| Age, Categorical Between 18 and 65 years | 5 Participants | 3 Participants | 8 Participants | 16 Participants |
| Age, Continuous | 64.33 years | 66.38 years | 59.33 years | 64.22 years |
| Region of Enrollment United States | 12 participants | 12 participants | 12 participants | 36 participants |
| Sex: Female, Male Female | 5 Participants | 8 Participants | 7 Participants | 20 Participants |
| Sex: Female, Male Male | 7 Participants | 0 Participants | 5 Participants | 12 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 12 | 0 / 12 | 0 / 8 |
| other Total, other adverse events | 2 / 12 | 0 / 12 | 2 / 8 |
| serious Total, serious adverse events | 0 / 12 | 0 / 12 | 0 / 8 |
Outcome results
Primary
Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium.
Samples were analyzed comparing the osteogenic potential associated with titanium and porous tantalum dental implants (cylinders) at 2 and 4 weeks using transcriptome analyses. The primary outcome data are displayed showing the Average Delta ∆ (Ct) for osteogenic genes relative to the housekeeping markers. The numerical value of the CT is inversely related to the amount of amplicon in the reaction (i.e., the lower the CT, the greater the amount of amplicon).
Time frame: 2 weeks & 4 weeks post placement
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Healthy/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | IGF1R (4 weeks) | 1.5259 Average Delta ∆ (Ct) | Standard Deviation 0.31 |
| Healthy/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | DLX5 (2 week) | 10.4258 Average Delta ∆ (Ct) | Standard Deviation 0.038 |
| Healthy/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | GLI1 (4 weeks) | 5.7365 Average Delta ∆ (Ct) | Standard Deviation 0.27 |
| Healthy/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGF2 (4 weeks) | 4.7981 Average Delta ∆ (Ct) | Standard Deviation 0.26 |
| Healthy/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BGN (2 Weeks) | 0.6525 Average Delta ∆ (Ct) | Standard Deviation 0.63 |
| Healthy/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP2 (2 weeks) | 7.6758 Average Delta ∆ (Ct) | Standard Deviation 0.12 |
| Healthy/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | IGF1 (4 weeks) | 0.5603 Average Delta ∆ (Ct) | Standard Deviation 1.09 |
| Healthy/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | PHEX (4 weeks) | 2.1578 Average Delta ∆ (Ct) | Standard Deviation 0.58 |
| Healthy/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | TGFBR2 (4weeks) | 0.3029 Average Delta ∆ (Ct) | Standard Deviation 0.25 |
| Healthy/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGFR1 (4 weeks) | 0.3229 Average Delta ∆ (Ct) | Standard Deviation 0.71 |
| Healthy/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | COL14A1 (2 weeks) | 2.9192 Average Delta ∆ (Ct) | Standard Deviation 0.52 |
| Healthy/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP1 (2 weeks) | 4.2225 Average Delta ∆ (Ct) | Standard Deviation 0.46 |
| Healthy/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP1 (4 weeks) | 3.6543 Average Delta ∆ (Ct) | Standard Deviation 0.43 |
| Healthy/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGFR2 (4 weeks) | 1.5910 Average Delta ∆ (Ct) | Standard Deviation 0.38 |
| Healthy/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP2 (4 weeks) | 7.0738 Average Delta ∆ (Ct) | Standard Deviation 1.26 |
| Healthy/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGF1 (4 weeks) | 4.0907 Average Delta ∆ (Ct) | Standard Deviation 0.19 |
| Healthy/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | CSF1 (2 weeks) | 5.2292 Average Delta ∆ (Ct) | Standard Deviation 0.51 |
| Healthy/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP2 (2 weeks) | 9.2208 Average Delta ∆ (Ct) | Standard Deviation 1.15 |
| Healthy/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | PHEX (4 weeks) | 6.4186 Average Delta ∆ (Ct) | Standard Deviation 2.08 |
| Healthy/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | IGF1R (4 weeks) | 3.8134 Average Delta ∆ (Ct) | Standard Deviation 1.08 |
| Healthy/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | GLI1 (4 weeks) | 8.2807 Average Delta ∆ (Ct) | Standard Deviation 0.23 |
| Healthy/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | IGF1 (4 weeks) | 3.3670 Average Delta ∆ (Ct) | Standard Deviation 1.25 |
| Healthy/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | DLX5 (2 week) | 12.2275 Average Delta ∆ (Ct) | Standard Deviation 1.08 |
| Healthy/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGFR1 (4 weeks) | 1.4584 Average Delta ∆ (Ct) | Standard Deviation 0.41 |
| Healthy/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP1 (2 weeks) | 5.9042 Average Delta ∆ (Ct) | Standard Deviation 0.84 |
| Healthy/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | CSF1 (2 weeks) | 6.4042 Average Delta ∆ (Ct) | Standard Deviation 0.23 |
| Healthy/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP2 (4 weeks) | 4.3821 Average Delta ∆ (Ct) | Standard Deviation 0.5 |
| Healthy/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGF2 (4 weeks) | 5.9102 Average Delta ∆ (Ct) | Standard Deviation 0.71 |
| Healthy/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BGN (2 Weeks) | 3.0942 Average Delta ∆ (Ct) | Standard Deviation 1.25 |
| Healthy/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP1 (4 weeks) | 2.2410 Average Delta ∆ (Ct) | Standard Deviation 0.59 |
| Healthy/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | TGFBR2 (4weeks) | 0.9102 Average Delta ∆ (Ct) | Standard Deviation 0.79 |
| Healthy/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGFR2 (4 weeks) | 3.8245 Average Delta ∆ (Ct) | Standard Deviation 1.98 |
| Healthy/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | COL14A1 (2 weeks) | 4.4442 Average Delta ∆ (Ct) | Standard Deviation 0.33 |
| Healthy/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGF1 (4 weeks) | 5.3543 Average Delta ∆ (Ct) | Standard Deviation 0.85 |
| Osteopenic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGF2 (4 weeks) | -0.9658 Average Delta ∆ (Ct) | Standard Deviation 1.33 |
| Osteopenic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP2 (4 weeks) | 3.3444 Average Delta ∆ (Ct) | Standard Deviation 1.3 |
| Osteopenic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP2 (2 weeks) | 4.6085 Average Delta ∆ (Ct) | Standard Deviation 2.67 |
| Osteopenic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | DLX5 (2 week) | 5.9966 Average Delta ∆ (Ct) | Standard Deviation 1.56 |
| Osteopenic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP1 (2 weeks) | 1.8624 Average Delta ∆ (Ct) | Standard Deviation 1.49 |
| Osteopenic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BGN (2 Weeks) | -1.9201 Average Delta ∆ (Ct) | Standard Deviation 0.31 |
| Osteopenic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | COL14A1 (2 weeks) | 0.5529 Average Delta ∆ (Ct) | Standard Deviation 0.42 |
| Osteopenic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | CSF1 (2 weeks) | 0.8180 Average Delta ∆ (Ct) | Standard Deviation 0.95 |
| Osteopenic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | GLI1 (4 weeks) | 4.8091 Average Delta ∆ (Ct) | Standard Deviation 0.33 |
| Osteopenic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | IGF1R (4 weeks) | 2.6811 Average Delta ∆ (Ct) | Standard Deviation 1.08 |
| Osteopenic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | PHEX (4 weeks) | 0.2916 Average Delta ∆ (Ct) | Standard Deviation 0.26 |
| Osteopenic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGF1 (4 weeks) | 2.5977 Average Delta ∆ (Ct) | Standard Deviation 0.23 |
| Osteopenic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGFR2 (4 weeks) | 0.8745 Average Delta ∆ (Ct) | Standard Deviation 0.1 |
| Osteopenic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | TGFBR2 (4weeks) | -0.9658 Average Delta ∆ (Ct) | Standard Deviation 1.74 |
| Osteopenic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGFR1 (4 weeks) | -0.5135 Average Delta ∆ (Ct) | Standard Deviation 0.2 |
| Osteopenic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | IGF1 (4 weeks) | 2.1275 Average Delta ∆ (Ct) | Standard Deviation 2.47 |
| Osteopenic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP1 (4 weeks) | 0.6949 Average Delta ∆ (Ct) | Standard Deviation 0.14 |
| Osteopenic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGFR1 (4 weeks) | -0.9003 Average Delta ∆ (Ct) | Standard Deviation 0.24 |
| Osteopenic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | GLI1 (4 weeks) | 4.7381 Average Delta ∆ (Ct) | Standard Deviation 1.41 |
| Osteopenic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BGN (2 Weeks) | -0.6761 Average Delta ∆ (Ct) | Standard Deviation 0.22 |
| Osteopenic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP1 (4 weeks) | 1.0592 Average Delta ∆ (Ct) | Standard Deviation 0.2 |
| Osteopenic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | TGFBR2 (4weeks) | -0.2509 Average Delta ∆ (Ct) | Standard Deviation 2.96 |
| Osteopenic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | IGF1R (4 weeks) | 3.0398 Average Delta ∆ (Ct) | Standard Deviation 0.3 |
| Osteopenic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGF2 (4 weeks) | 4.2644 Average Delta ∆ (Ct) | Standard Deviation 1.97 |
| Osteopenic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP1 (2 weeks) | 2.4895 Average Delta ∆ (Ct) | Standard Deviation 1.31 |
| Osteopenic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP2 (2 weeks) | 5.2331 Average Delta ∆ (Ct) | Standard Deviation 1.69 |
| Osteopenic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGF1 (4 weeks) | 3.1967 Average Delta ∆ (Ct) | Standard Deviation 1.77 |
| Osteopenic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | PHEX (4 weeks) | 3.9890 Average Delta ∆ (Ct) | Standard Deviation 0.41 |
| Osteopenic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | IGF1 (4 weeks) | 1.8615 Average Delta ∆ (Ct) | Standard Deviation 0.4 |
| Osteopenic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | COL14A1 (2 weeks) | 0.9162 Average Delta ∆ (Ct) | Standard Deviation 0.66 |
| Osteopenic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | DLX5 (2 week) | 6.1543 Average Delta ∆ (Ct) | Standard Deviation 1.75 |
| Osteopenic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | CSF1 (2 weeks) | 2.1533 Average Delta ∆ (Ct) | Standard Deviation 0.81 |
| Osteopenic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGFR2 (4 weeks) | 2.9709 Average Delta ∆ (Ct) | Standard Deviation 0.34 |
| Osteopenic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP2 (4 weeks) | 3.6476 Average Delta ∆ (Ct) | Standard Deviation 0.94 |
| Diabetic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | CSF1 (2 weeks) | 4.5506 Average Delta ∆ (Ct) | Standard Deviation 1.39 |
| Diabetic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | PHEX (4 weeks) | 5.7960 Average Delta ∆ (Ct) | Standard Deviation 1.62 |
| Diabetic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | COL14A1 (2 weeks) | 2.4111 Average Delta ∆ (Ct) | Standard Deviation 1.31 |
| Diabetic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGF1 (4 weeks) | 6.3124 Average Delta ∆ (Ct) | Standard Deviation 4.51 |
| Diabetic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP2 (4 weeks) | 7.1463 Average Delta ∆ (Ct) | Standard Deviation 2.56 |
| Diabetic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGFR2 (4 weeks) | 4.3674 Average Delta ∆ (Ct) | Standard Deviation 2.19 |
| Diabetic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BGN (2 Weeks) | 0.9032 Average Delta ∆ (Ct) | Standard Deviation 1.86 |
| Diabetic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | TGFBR2 (4weeks) | 2.2868 Average Delta ∆ (Ct) | Standard Deviation 1.89 |
| Diabetic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP1 (2 weeks) | 3.9986 Average Delta ∆ (Ct) | Standard Deviation 1.77 |
| Diabetic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGF2 (4 weeks) | 6.8459 Average Delta ∆ (Ct) | Standard Deviation 3.2 |
| Diabetic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | DLX5 (2 week) | 9.4077 Average Delta ∆ (Ct) | Standard Deviation 1.09 |
| Diabetic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGFR1 (4 weeks) | 2.4234 Average Delta ∆ (Ct) | Standard Deviation 2.36 |
| Diabetic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP1 (4 weeks) | 3.9986 Average Delta ∆ (Ct) | Standard Deviation 2.71 |
| Diabetic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | IGF1 (4 weeks) | 4.2738 Average Delta ∆ (Ct) | Standard Deviation 1.55 |
| Diabetic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP2 (2 weeks) | 7.1463 Average Delta ∆ (Ct) | Standard Deviation 1.67 |
| Diabetic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | GLI1 (4 weeks) | 8.7988 Average Delta ∆ (Ct) | Standard Deviation 3.77 |
| Diabetic/Tantalum | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | IGF1R (4 weeks) | 5.6048 Average Delta ∆ (Ct) | Standard Deviation 2.31 |
| Diabetic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | COL14A1 (2 weeks) | 3.0112 Average Delta ∆ (Ct) | Standard Deviation 1.18 |
| Diabetic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGFR1 (4 weeks) | 2.7818 Average Delta ∆ (Ct) | Standard Deviation 2.16 |
| Diabetic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BGN (2 Weeks) | .03906 Average Delta ∆ (Ct) | Standard Deviation 2.3 |
| Diabetic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP2 (2 weeks) | 6.5207 Average Delta ∆ (Ct) | Standard Deviation 1.73 |
| Diabetic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | CSF1 (2 weeks) | 4.6397 Average Delta ∆ (Ct) | Standard Deviation 1.21 |
| Diabetic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGF1 (4 weeks) | 5.8513 Average Delta ∆ (Ct) | Standard Deviation 0.53 |
| Diabetic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | PHEX (4 weeks) | 6.8678 Average Delta ∆ (Ct) | Standard Deviation 0.8 |
| Diabetic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | IGF1 (4 weeks) | 5.4869 Average Delta ∆ (Ct) | Standard Deviation 1.68 |
| Diabetic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP2 (4 weeks) | 6.5207 Average Delta ∆ (Ct) | Standard Deviation 0.91 |
| Diabetic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP1 (2 weeks) | 3.5056 Average Delta ∆ (Ct) | Standard Deviation 1.57 |
| Diabetic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | TGFBR2 (4weeks) | 2.9935 Average Delta ∆ (Ct) | Standard Deviation 1.23 |
| Diabetic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | IGF1R (4 weeks) | 6.3467 Average Delta ∆ (Ct) | Standard Deviation 0.65 |
| Diabetic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGF2 (4 weeks) | 7.7363 Average Delta ∆ (Ct) | Standard Deviation 1.34 |
| Diabetic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | DLX5 (2 week) | 9.4038 Average Delta ∆ (Ct) | Standard Deviation 1.12 |
| Diabetic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | GLI1 (4 weeks) | 9.1999 Average Delta ∆ (Ct) | Standard Deviation 2.04 |
| Diabetic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | BMP1 (4 weeks) | 1.5697 Average Delta ∆ (Ct) | Standard Deviation 1.63 |
| Diabetic/Titanium | Fold Change in Gene Expression Comparing Trabecular Metal to Standard Titanium. | FGFR2 (4 weeks) | 5.4090 Average Delta ∆ (Ct) | Standard Deviation 0.71 |
Secondary
Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks.
Findings from expression arrays will be used to perform quantitative PCR analyses using SAB Superarrays (SuperArray GEArray), to enable a quantitativeassay of mRNA levels of specific inflammatory and growth factor molecules
Time frame: 4 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Healthy/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | GLI1 | 5.736 Fold Change | Standard Deviation 0.27 |
| Healthy/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | BMP2 | 7.074 Fold Change | Standard Deviation 1.26 |
| Healthy/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGF1 | 40.91 Fold Change | Standard Deviation 0.19 |
| Healthy/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | PHEX | 2.158 Fold Change | Standard Deviation 0.58 |
| Healthy/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | CSF1 | 5.229 Fold Change | Standard Deviation 0.51 |
| Healthy/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | IGF1 | 0.56 Fold Change | Standard Deviation 1.09 |
| Healthy/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGFR2 | 1.591 Fold Change | Standard Deviation 0.38 |
| Healthy/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGF2 | 4.79 Fold Change | Standard Deviation 0.26 |
| Healthy/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | IGF1R | 1.526 Fold Change | Standard Deviation 0.31 |
| Healthy/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | BMP1 | 3.654 Fold Change | Standard Deviation 0.43 |
| Healthy/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGFR1 | 0.323 Fold Change | Standard Deviation 0.71 |
| Healthy/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | TGFBR2 | 0.303 Fold Change | Standard Deviation 0.25 |
| Healthy/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGF2 | 5.910 Fold Change | Standard Deviation 0.71 |
| Healthy/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | TGFBR2 | 0.901 Fold Change | Standard Deviation 0.79 |
| Healthy/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | CSF1 | 6.404 Fold Change | Standard Deviation 0.23 |
| Healthy/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | BMP1 | 2.241 Fold Change | Standard Deviation 0.59 |
| Healthy/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | GLI1 | 8.281 Fold Change | Standard Deviation 0.23 |
| Healthy/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | PHEX | 6.419 Fold Change | Standard Deviation 2.08 |
| Healthy/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | IGF1R | 3.813 Fold Change | Standard Deviation 1.08 |
| Healthy/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | BMP2 | 4.382 Fold Change | Standard Deviation 0.5 |
| Healthy/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGF1 | 5.3454 Fold Change | Standard Deviation 0.85 |
| Healthy/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | IGF1 | 3.367 Fold Change | Standard Deviation 1.25 |
| Healthy/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGFR2 | 3.824 Fold Change | Standard Deviation 1.98 |
| Healthy/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGFR1 | 1.458 Fold Change | Standard Deviation 0.41 |
| Osteopenic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | GLI1 | 8.799 Fold Change | Standard Deviation 3.77 |
| Osteopenic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | PHEX | 5.796 Fold Change | Standard Deviation 1.62 |
| Osteopenic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGFR2 | 4.367 Fold Change | Standard Deviation 2019 |
| Osteopenic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | TGFBR2 | 2.287 Fold Change | Standard Deviation 1.89 |
| Osteopenic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGF2 | 6.846 Fold Change | Standard Deviation 3.2 |
| Osteopenic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGFR1 | 2.423 Fold Change | Standard Deviation 2.36 |
| Osteopenic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | IGF1 | 4.2474 Fold Change | Standard Deviation 1.55 |
| Osteopenic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | BMP2 | 7.146 Fold Change | Standard Deviation 2.56 |
| Osteopenic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | BMP1 | 3.999 Fold Change | Standard Deviation 2.71 |
| Osteopenic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | CSF1 | 4.551 Fold Change | Standard Deviation 1.39 |
| Osteopenic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGF1 | 6.312 Fold Change | Standard Deviation 4.51 |
| Osteopenic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | IGF1R | 5.605 Fold Change | Standard Deviation 2.31 |
| Osteopenic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | TGFBR2 | 2.994 Fold Change | Standard Deviation 1.23 |
| Osteopenic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGF1 | 5.851 Fold Change | Standard Deviation 0.53 |
| Osteopenic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | BMP2 | 6.521 Fold Change | Standard Deviation 0.91 |
| Osteopenic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGFR1 | 2.782 Fold Change | Standard Deviation 2.16 |
| Osteopenic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | GLI1 | 9.2 Fold Change | Standard Deviation 2.04 |
| Osteopenic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | PHEX | 6.868 Fold Change | Standard Deviation 0.8 |
| Osteopenic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGF2 | 7.736 Fold Change | Standard Deviation 1.34 |
| Osteopenic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | IGF1 | 5.487 Fold Change | Standard Deviation 1.68 |
| Osteopenic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | BMP1 | 1.570 Fold Change | Standard Deviation 1.63 |
| Osteopenic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | CSF1 | 4.64 Fold Change | Standard Deviation 1.21 |
| Osteopenic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGFR2 | 5.409 Fold Change | Standard Deviation 0.71 |
| Osteopenic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | IGF1R | 6.347 Fold Change | Standard Deviation 0.65 |
| Diabetic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | CSF1 | 0.818 Fold Change | Standard Deviation 0.95 |
| Diabetic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | IGF1R | 2.681 Fold Change | Standard Deviation 1.08 |
| Diabetic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | TGFBR2 | -0.966 Fold Change | Standard Deviation 1.74 |
| Diabetic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | GLI1 | 4.809 Fold Change | Standard Deviation 0.33 |
| Diabetic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGF2 | -0.966 Fold Change | Standard Deviation 1.33 |
| Diabetic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGFR2 | 0.875 Fold Change | Standard Deviation 0.1 |
| Diabetic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | PHEX | 0.292 Fold Change | Standard Deviation 0.26 |
| Diabetic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | BMP2 | 3.344 Fold Change | Standard Deviation 1.3 |
| Diabetic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGF1 | 2.598 Fold Change | Standard Deviation 0.23 |
| Diabetic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGFR1 | -0.513 Fold Change | Standard Deviation 0.2 |
| Diabetic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | BMP1 | 0.695 Fold Change | Standard Deviation 0.14 |
| Diabetic/Tantalum | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | IGF1 | 2.128 Fold Change | Standard Deviation 2.47 |
| Diabetic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGF2 | 4.264 Fold Change | Standard Deviation 1.97 |
| Diabetic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | GLI1 | 4.738 Fold Change | Standard Deviation 1.41 |
| Diabetic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGFR1 | -0.9 Fold Change | Standard Deviation 0.24 |
| Diabetic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGF1 | 3.197 Fold Change | Standard Deviation 1.77 |
| Diabetic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | IGF1 | 1.861 Fold Change | Standard Deviation 0.4 |
| Diabetic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | PHEX | 3.989 Fold Change | Standard Deviation 0.41 |
| Diabetic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | BMP2 | 3.648 Fold Change | Standard Deviation 0.94 |
| Diabetic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | CSF1 | 2.153 Fold Change | Standard Deviation 0.81 |
| Diabetic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | IGF1R | 3.04 Fold Change | Standard Deviation 0.3 |
| Diabetic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | BMP1 | 1.059 Fold Change | Standard Deviation 0.2 |
| Diabetic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | TGFBR2 | -0.251 Fold Change | Standard Deviation 2.96 |
| Diabetic/Titanium | Group Based Differences (i.e. Healthy, Osteopenic and Diabetic) in Gene Expression Using Fold Changes Between Titanium and Trabecular at 4 Weeks. | FGFR2 | 2.971 Fold Change | Standard Deviation 0.34 |